CN104230893A - 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2 - Google Patents

2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2 Download PDF

Info

Publication number
CN104230893A
CN104230893A CN201410190297.2A CN201410190297A CN104230893A CN 104230893 A CN104230893 A CN 104230893A CN 201410190297 A CN201410190297 A CN 201410190297A CN 104230893 A CN104230893 A CN 104230893A
Authority
CN
China
Prior art keywords
crystalline form
methylpyrrolidin
benzimidazole
abt
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410190297.2A
Other languages
English (en)
Chinese (zh)
Inventor
G·朱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aibo Wei Ireland Ltd.
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN104230893A publication Critical patent/CN104230893A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201410190297.2A 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2 Pending CN104230893A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97965407P 2007-10-12 2007-10-12
US60/979654 2007-10-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880111585.7A Division CN101821269B (zh) 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Publications (1)

Publication Number Publication Date
CN104230893A true CN104230893A (zh) 2014-12-24

Family

ID=40279000

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410190297.2A Pending CN104230893A (zh) 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
CN200880111585.7A Expired - Fee Related CN101821269B (zh) 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880111585.7A Expired - Fee Related CN101821269B (zh) 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Country Status (8)

Country Link
US (1) US8013168B2 (enExample)
EP (2) EP2727921B1 (enExample)
JP (3) JP2011500588A (enExample)
CN (2) CN104230893A (enExample)
CA (1) CA2696423A1 (enExample)
ES (1) ES2562081T3 (enExample)
MX (1) MX2010003771A (enExample)
WO (1) WO2009049109A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071499A (zh) * 2016-03-09 2018-12-21 苏州晶云药物科技股份有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722046B1 (en) * 2007-10-12 2016-12-21 AbbVie Ireland Unlimited Company 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1
NZ616227A (en) * 2011-04-11 2016-01-29 Abb Vie Inc Parp inhibitors for the treatment of cipn
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032579A1 (de) * 1998-11-27 2000-06-08 Basf Aktiengesellschaft Substituierte benzimidazole und ihre verwendung als parp inhibitoren
WO2001082877A2 (de) * 2000-05-04 2001-11-08 Basf Aktiengesellschaft Verwendung von parp-inhibitoren in kosmetischen zubereitungen
US20060229289A1 (en) * 2005-04-11 2006-10-12 Gui-Dong Zhu 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
CN1926127A (zh) * 2003-12-29 2007-03-07 万有制药株式会社 新的2－杂芳基取代苯并咪唑衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
EP2722046B1 (en) 2007-10-12 2016-12-21 AbbVie Ireland Unlimited Company 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032579A1 (de) * 1998-11-27 2000-06-08 Basf Aktiengesellschaft Substituierte benzimidazole und ihre verwendung als parp inhibitoren
WO2001082877A2 (de) * 2000-05-04 2001-11-08 Basf Aktiengesellschaft Verwendung von parp-inhibitoren in kosmetischen zubereitungen
CN1926127A (zh) * 2003-12-29 2007-03-07 万有制药株式会社 新的2－杂芳基取代苯并咪唑衍生物
US20060229289A1 (en) * 2005-04-11 2006-10-12 Gui-Dong Zhu 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071499A (zh) * 2016-03-09 2018-12-21 苏州晶云药物科技股份有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法

Also Published As

Publication number Publication date
EP2217603B1 (en) 2015-11-18
CN101821269A (zh) 2010-09-01
US20090099246A1 (en) 2009-04-16
EP2727921B1 (en) 2017-04-19
EP2727921A1 (en) 2014-05-07
EP2217603A1 (en) 2010-08-18
JP2011500588A (ja) 2011-01-06
JP2014237660A (ja) 2014-12-18
MX2010003771A (es) 2010-04-21
CA2696423A1 (en) 2009-04-16
ES2562081T3 (es) 2016-03-02
US8013168B2 (en) 2011-09-06
JP2017071617A (ja) 2017-04-13
WO2009049109A1 (en) 2009-04-16
CN101821269B (zh) 2014-05-28

Similar Documents

Publication Publication Date Title
JP2019001811A (ja) ２−（（ｒ）−２−メチルピロリジン−２−イル）−１ｈ−ベンズイミダゾール−４−カルボキサミド結晶型１
JP2017071617A (ja) ２−（（ｒ）−２−メチルピロリジン−２−イル）−１ｈ−ベンズイミダゾール−４−カルボキサミド結晶型２
CN101827824B (zh) 结晶化学治疗剂
US8486988B2 (en) Crystalline chemotherapeutic
US8759538B1 (en) Crystalline chemotherapeutic
HK1197642B (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
HK1197642A (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20161011

Address after: Bermuda Hamilton

Applicant after: Aibo Wei Ireland Ltd.

Address before: Bahamas Nassau

Applicant before: ABBOTT LABAORATORIES

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141224

WD01 Invention patent application deemed withdrawn after publication